FDAsafety guidance66% confidence
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sciegen Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
The 21st Century Cures Act formally established a multi-step process for Drug Development Tools (DDT) qualification. Qualification of DDT is for a specific context of use (COU), and the qualified DDT may be used for the COU by any person in drug or biologics development.
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: FDA Submission Overview for Dapagliflozin by Sciegen Pharmaceuticals